Cryo-Cell International, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $31.5M
- Price
- $3.91
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 4.0K
About
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Quick stats
Shares outstanding8.1M
Computed float5.2M
Float / shares64.2%
Key info
SectorHealthcare
IndustryMedical - Care Facilities
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000862692
Websitehttps://www.cryo-cell.com
AI Summary
AI-generated1/4
minormixedearnings
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results
Cryo-Cell reported fiscal Q2 2026 revenue of $7.8 million, a 2% decrease from the prior year's $7.9 million.
Despite the revenue decline, net income improved to $555,000, or $0.07 per share, compared to $356,000, or $0.04 per share, in the same period last year.
The company operates as a private cord blood bank and holds exclusive rights to the PrepaCyte-CB processing technology, maintaining its focus on regenerative medicine.
Red flags
- Revenue declined 2% year-over-year